Mutation detail:
| Mutation site | K417N/E484K/Q493R |
| Virus | SARS-CoV-2 |
Mutation level  |
Amino acid level |
| Gene/protein/region type | S |
| Gene ID | 43740568 |
| Country | USA |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | 20A |
| Sample |
Human |
| Variants | Alpha |
| Viral reference sequence | MN908947.3 |
| Drug/antibody/vaccine | Bamlanivimab resistant/Etesevimab resistant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | Yes |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Spike glycoprotein |
| Uniprot protein ID | P0DTC2 |
| Protein length | 1273 amino acids |
| Protein description | Spike protein is one of the structural proteins of SARS-CoV-2. The monomeric protein consists of one large ectodomain, a single-pass transmembrane anchor, and a short intracellular tail at C-terminus. It encompasses 22 glycosylation sites. S protein cleaves into two subunits namely S1 and S2 following receptor recognition. Receptor Binding Domain (RBD) in S1 subunit plays a major role in ACE2 receptor binding. |
Literature information:
| Pubmed ID | 34876033 |
| Clinical information | No |
| Disease | - |
| Published year | 2021 |
| Journal | BMC INFECTIOUS DISEASES |
| Title | BMC INFECTIOUS DISEASES |
| Author | Honorine Fenaux, Romain Gueneau, Amal Chaghouri, Benoit Henry, Lina Mouna |
| Evidence | Sanger sequencing of the S gene was performed on three samples and analysed on SeqScape 4 software, aligned on reference sequence 20A.EU2. It showed a typical B1.1.7 variant on the first sample (April 13th); double populations: K417K/N, E484E/K and Q493Q/R on the 2nd sample (28th April), and E484K and K417N on the 3rd sample (May 8th) (Fig. 4). |